Seres Therapeutics (MCRB) Work In Process (2023 - 2024)
Seres Therapeutics' (MCRB) quarterly Work In Process came in at $48.1 million in Q2 2024, up 911.85% year-over-year from $4.8 million in Q3 2023, and up 28.98% quarter-over-quarter from $37.3 million in Q1 2024.
Powered by 
Analysis
Seres Therapeutics (MCRB) Work In Process (2023 - 2024) Analysis & Trends
Seres Therapeutics has disclosed Work In Process across 2 years of filings, most recently posting $48.1 million for Q2 2024.
- In Q2 2024, Work In Process rose 911.85% year-over-year to $48.1 million; the TTM figure through Jun 2024 stood at $48.1 million (up 911.85% YoY), while the FY2023 annual figure was $25.2 million, changed N/A from the prior year.
- Work In Process came in at $48.1 million for Q2 2024 at Seres Therapeutics, up from $37.3 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $48.1 million in Q2 2024 to a low of $4.8 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Seres Therapeutics | 49.89 Mn | 49.89 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 48.06 Mn |
| Mar 31, 2024 | 37.27 Mn |
| Dec 31, 2023 | 25.22 Mn |
| Sep 30, 2023 | 14.99 Mn |
| Jun 30, 2023 | 4.75 Mn |